Open AccessArticle Hearing Outcomes During Induction Therapy in ANCA-Associated Vasculitis: Applicability of Sudden Sensorineural Hearing Loss Criteria 1 Department of Otolaryngology and Laryngological Oncology with Clinical Department of Craniofacial Surgery, Military Institute of Medicine—National Research Institute, Szaserów 128, 04-349 Warsaw, Poland 2 Department of Biophysics, Physiology and Pathophysiology, Medical University of Warsaw, 02-901 Warsaw, Poland 3 Department of Internal Diseases, Nephrology and Dialysis, Military Institute of Medicine—National Research Institute, Szaserów 128, 04-349 Warsaw, Poland * Authors to whom correspondence should be addressed. J. Clin. Med. 2026, 15(11), 4349; https://doi.org/10.3390/jcm15114349 (registering DOI) Submission received: 21 April 2026 / Revised: 27 May 2026 / Accepted: 2 June 2026 / Published: 4 June 2026 Abstract Objectives: ANCA-associated vasculitis (AAV) is a relapsing–remitting systemic disease in which auditory involvement is increasingly recognized as a determinant of quality of life. The objective of this study was to evaluate hearing outcomes during induction therapy in AAV and to assess the applicability of sudden sensorineural hearing loss (SSNHL) criteria for monitoring treatment response. Methods: A prospective study included 27 patients with AAV hospitalized at the Department of Internal Medicine, Nephrology and Dialysis, Military Institute of Medicine–National Research Institute. Audiologic assessment included pure-tone audiometry (including high-frequency audiometry), immittance audiometry, otoacoustic emissions, and auditory brainstem response (ABR). Examinations were performed at baseline (induction phase) and after remission. Hearing outcomes were evaluated using SSNHL criteria defined by the Ministry of Health and Welfare of Japan. Associations between hearing loss and organ involvement were also analyzed. Results: Improvement to normal hearing in pure-tone audiometry was observed in three ears, while deterioration from normal hearing occurred in four ears. No statistically significant differences were found in overall otoacoustic emission responses between baseline and follow-up. A statistically significant association was identified between hearing loss and peripheral nervous system involvement (50.0% vs. 11.1%, p = 0.057). No significant correlations were observed between hearing outcomes and other clinical parameters. Conclusions: SSNHL-based hearing outcome criteria may represent a practical tool for assessing auditory dysfunction and monitoring treatment response in AAV. High-frequency audiometry and structured outcome measures may improve detection of subtle cochlear changes. Further studies with larger cohorts are required to validate these findings and clarify the relationship between systemic disease activity and hearing impairment. Keywords: ANCA; SSNHL; hearing loss; vasculitis; AAV 2. Patients and Methods 2.1. Patients The study cohort consisted of patients with proteinase 3 (PR3)-ANCA and myeloperoxidase (MPO)-ANCA hospitalized at the Department of Internal Medicine, Nephrology and Dialysis, Military Institute of Medicine–National Research Institute between December 2023 and February 2025. All patients were evaluated during the active phase of inflammation, either at first or subsequent induction therapy, regardless of self-reported hearing impairment. The first visit was carried out at the time of qualification for AAV remission-inducing treatment, and the second visit after the completion of this treatment. Informed consent was obtained from all individual participants included in the study. Diagnosis of GPA and MPA was established according to the 2022 ACR/EULAR classification criteria [ 7, 8]. Two rituximab (RTX) induction regimens were used: the RAVE protocol (375 mg/m 2 weekly for four weeks), approved in the European Union for induction of remission in GPA and MPA [ 9], and a two-dose regimen (1 g at weeks 0 and 2), originally approved for rheumatoid arthritis [ 10]. In cases of severe renal involvement, a combination of RTX infusions and two pulses of intravenous cyclophosphamide was administered [ 11]. For the purpose of analysis, all RTX-based regimens were categorized as a single RTX treatment group. Intravenous pulse cyclophosphamide was administered according to the CYCLOPS protocol [ 12]. Exclusion criteria included congenital or early-onset deafness unrelated to vasculitic ear involvement (excluded affected ear), exposure to ototoxic medications (gentamicin, amikacin, tobramycin, high-dose furosemide, erythromycin, high-dose aspirin, cisplatin, or quinine), prior head and neck radiotherapy, meningitis, hereditary hearing disorders, and previous ear surgery unrelated to vasculitis (excluded operated ear). All patients completed standardized questionnaires to obtain baseline clinical data. Disease activity was assessed using the Birmingham Vasculitis Activity Score for Wegener’s Granulomatosis (BVAS/WG). Additional variables included disease duration and number of relapses [ 13]. 2.2. Audiologic Assessment All participants underwent comprehensive audiologic evaluation at baseline (initiation of induction therapy) and after approximately six months, corresponding to the expected remission phase. The test battery included pure-tone audiometry (standard and high-frequency ranges), immittance audiometry, otoacoustic emissions (OAEs), and auditory brainstem response (ABR). Pure-tone audiometry was performed using an Interacoustics AC40 audiometer (Interacoustics headquarters, Audiometer Allé 1, Middelfart, Denmark) with Sennheiser HDA 300 headphones. Air conduction thresholds were measured across standard frequencies (125–8000 Hertz (Hz)) and extended high frequencies (9000–16,000 Hz), while bone conduction thresholds were assessed within the conventional range (125–4000 Hz). Masking was applied when appropriate. Hearing loss was defined as a pure-tone average (PTA) > 20 decibels (dB). The conventional PTA Air Conduction/Bone Conduction (PTA AC/BC) was calculated as the mean threshold at 500, 1000, 2000, and 4000 Hz and classified according to World Health Organization criteria [ 14]. Additionally, a High-Frequency PTA (HF-PTA) was calculated as the mean threshold between 9000 and 12,500 Hz [ 15]. Hearing severity and treatment-related improvement were evaluated according to the Japanese Ministry of Health criteria for sudden sensorineural hearing loss. Hearing deterioration was graded based on PTA values ( 0.5) were analyzed. Wave morphology and reproducibility were also assessed to ensure recording reliability. ABR findings were used to support the diagnosis and localization of sensorineural hearing loss but were not included in statistical analyses. 2.3. Statistical Analysis Data were analyzed using Statistica software (version 13.3; TIBCO Software Inc., Palo Alto, CA, USA). Quantitative variables were summarized using descriptive statistics, including the mean, standard deviation (SD), median, and range. Categorical variables were expressed as frequencies and percentages. Associations between categorical variables were assessed using the chi-square test or Fisher’s exact test, as appropriate. The normality of quantitative variable distributions was evaluated using the Shapiro–Wilk test. As the assumption of normality was not met, comparisons between pre- and post-treatment measurements were performed using the Wilcoxon signed-rank test. A significance level of α = 0.05 was applied. 3. Results 3.1. General Characteristics The study included 27 patients, comprising 16 men (59.3%) and 11 women (40.7%), hospitalized at the Department of Internal Diseases, Nephrology and Dialysis, Military Institute of Medicine—National Research Institute between December 2023 and September 2025. The mean age was 54.7 ± 14.8 years (median 56 years, range 20–77 years). The mean disease duration was 16.5 ± 32.5 months (median 2 months; range 0–163 months). Among the patients, 20 (74.1%) experienced their first manifestation of the disease, 5 (18.5%) their second, and 2 (7.4%) their third. The mean BVAS-WG score was 9.4 ± 4.2 (median 9, range 1–20). Sixteen (59.3%) of the 27 patients were treated with RTX, while 11 (40.7%) received CF. Among the 27 patients, 16 were positive for PR3 ANCA, nine for MPO ANCA, and two were double negative. The mean interval between first and second visit was 6.72 ± 1.76 months (range 3–8 months). 4. Discussion Monitoring hearing outcomes after systemic therapy is a critical component of audiologic care, particularly in disorders with inflammatory or immune-mediated pathophysiology. Among otologic entities, sudden sensorineural hearing loss remains the most extensively investigated condition with respect to prognosis and treatment response. With an annual incidence of 5–20 cases per 100,000 individuals, SSNHL has provided a framework for defining recovery criteria and therapeutic endpoints in cochlear disorders [ 16]. Although its exact pathophysiology remains incompletely elucidated, vascular compromise, immune-mediated injury, and viral-triggered inflammation have all been implicated. These mechanisms overlap conceptually with those proposed in ANCA-associated vasculitis (AAV), making SSNHL criteria a reasonable reference model for outcome assessment in vasculitis-related hearing loss. Auditory involvement in AAV has gained increasing attention as overall survival improves and quality-of-life outcomes become more clinically relevant. Histopathologic and imaging studies suggest that cochlear dysfunction in AAV is predominantly related to inflammation of the stria vascularis and small-vessel vasculitis within the cochlear microcirculation [ 3]. The stria vascularis plays a central role in maintaining the endocochlear potential and ionic homeostasis; therefore, even subtle inflammatory or ischemic injury may disrupt outer hair cell function and high-frequency hearing before affecting conventional PTA thresholds. This microvascular hypothesis provides a biologically plausible explanation for the early vulnerability of basal cochlear regions in AAV. Notably, conductive hearing loss was more frequently observed in patients with shorter disease duration, whereas sensorineural hearing loss predominated in patients with longer-standing disease, suggesting that middle ear involvement may be particularly relevant in earlier disease stages, while cochlear dysfunction may become more prominent over time ( Table 5). This pattern may reflect the underlying pathophysiology. In immune-mediated cochlear injury, structural damage to outer hair cells or spiral ganglion neurons may become irreversible once a certain threshold of ischemic or inflammatory insult is exceeded. Therefore, partial improvement may represent restoration of microvascular perfusion and resolution of inflammatory edema rather than true regeneration of sensory structures. To standardize outcome assessment, we applied the Japanese Ministry of Health grading system for SSNHL [ 5, 17], aiming to determine its applicability in AAV-related hearing impairment. In our cohort of 27 patients (50 ears), sensorineural hearing loss was the predominant subtype (24%). Only four ears fulfilled criteria for slight improvement. Although these changes did not reach statistical significance, the observed pattern suggests that recovery, when present, tends to occur in ears with moderate baseline impairment and in those with mixed or conductive components. The most frequent shift in hearing grade was from Grade III to Grade II ( Table 2), indicating partial rather than complete cochlear recovery. An important aspect of the present study was not only the assessment of hearing changes during induction therapy, but also the evaluation of whether an established outcome classification could be pragmatically adapted to AAV-related hearing impairment. Unlike idiopathic SSNHL, hearing loss in AAV may be bilateral, fluctuate over time, or occur in patients with pre-existing hearing deficits, making some conventional recovery classifications less directly applicable. In this context, the Japanese Ministry of Health and Welfare SSNHL criteria offered several practical advantages, including independence from contralateral ear comparison, no requirement for knowledge of premorbid hearing status, and reliance on pure-tone audiometry as the principal outcome measure. Although originally developed for idiopathic SSNHL, this framework allowed structured grading of both baseline hearing severity and treatment-related improvement in our cohort. Given the absence of disease-specific audiologic outcome classifications for AAV, such standardized approaches may improve comparability between future studies. High-frequency audiometry (HFA) provides additional insight into this process. High-frequency thresholds are particularly sensitive to early cochlear compromise due to the tonotopic arrangement of the organ of Corti, where basal regions encoding higher frequencies are metabolically active and structurally exposed. In a Japanese nationwide SSNHL survey, complete or marked recovery occurred in 30% of cases, partial recovery in 30%, and no recovery in 40%, with profound baseline deafness associated with irreversible loss [ 18]. In our cohort, slight improvement in HFA was observed in six of 35 ears. Importantly, in our recent study we demonstrated that patients with AAV and normal conventional PTA (500–4000 Hz) already exhibit significantly elevated thresholds above 8000 Hz compared with controls without AAV [ 19]. This finding supports the concept that high-frequency dysfunction may represent a subclinical marker of early cochlear vasculitis. Consequently, even modest improvement in HFA may indicate restoration of cochlear microcirculation and stabilization of inflammatory activity. From a translational perspective, HFA may therefore serve as a functional biomarker of reversible microvascular injury. Frequency-specific analysis revealed statistically significant improvement at 6000 Hz and deterioration at 10,000 Hz, suggesting a non-uniform cochlear response to treatment. Given the exploratory nature of this analysis and the limited sample size, mechanistic interpretation should remain cautious. These observations may also reflect measurement variability, test–retest differences, or other patient-related confounding factors. Nonetheless, the findings may indicate that conventional summary measures alone do not fully capture treatment-related auditory changes in AAV, supporting the complementary role of frequency-specific assessment. All patients achieved complete (BVAS/WG = 0) or partial (BVAS/WG = 1–2) remission of the AAV after immunosuppressive treatment, with a mean baseline BVAS/WG score of 9.4 ± 4.2, confirming active systemic disease at inclusion. However, neither baseline disease activity nor the magnitude of BVAS/WG improvement correlated significantly with hearing outcomes. This dissociation suggests that systemic clinical remission does not necessarily equate to complete resolution of cochlear inflammation. The inner ear, characterized by limited regenerative capacity and specialized microvascular architecture, may exhibit delayed or incomplete functional recovery compared with other organs. Peripheral nervous system involvement was more frequently observed in patients with hearing loss. However, ABR testing did not reveal abnormalities in absolute latencies or interpeak intervals, arguing against retrocochlear or neural conduction pathology as the primary mechanism of sensorineural hearing loss in this cohort. These findings further support a predominantly cochlear rather than neural origin of auditory dysfunction in AAV. No statistically significant differences in hearing outcomes were observed between rituximab and cyclophosphamide. Nonetheless, a higher proportion of slight improvement was noted in the rituximab group (9.7% vs. 5.3%). Given rituximab’s targeted B-cell depletion and its impact on ANCA production, it is conceivable that more precise immunomodulation may confer subtle advantages in microvascular stabilization. However, these observations remain exploratory and require validation in larger, prospective cohorts. Otoacoustic emission (OAE) analysis did not demonstrate statistically significant improvement between visits ( Table 4). Although DPOAEs and TEOAEs are sensitive indicators of outer hair cell integrity, their variability and susceptibility to noise may limit their utility in systemic inflammatory conditions. Prior reports have described reappearance of DPOAEs following remission [ 20]; however, in our cohort, OAE recovery was modest. In our previous study, we showed that OAEs may lack sufficient sensitivity for detecting early cochlear deterioration in AAV [ 19]. Nevertheless, DPOAEs—given their frequency specificity—may still provide complementary information during longitudinal monitoring, particularly when interpreted alongside HFA. ABR findings were consistent with predominantly cochlear rather than retrocochlear sensorineural hearing loss. Mean wave V latency was 6.0 ± 0.4 ms (median 6.0 ms; range 5.4–7.1 ms) at baseline and 5.9 ± 0.4 ms (median 5.9 ms; range 5.2–7.2 ms) at follow-up, without evidence of clinically relevant conduction abnormalities. Immittance audiometry findings suggest that auditory involvement in AAV is clinically heterogeneous and cannot be attributed exclusively to cochlear dysfunction ( Table 5). Although tympanometric type A curves predominated in our cohort, a substantial subset of ears demonstrated conductive or mixed hearing loss, as well as abnormal tympanometric patterns consistent with middle ear dysfunction. These abnormalities were more frequent in patients with shorter disease duration, suggesting that middle ear involvement may be particularly relevant in earlier disease stages. Improvement in tympanometric findings during follow-up indicates that at least some conductive components may be dynamic and potentially reversible. This observation is consistent with the recognized spectrum of otologic manifestations in AAV, including Eustachian tube dysfunction, middle ear effusion, and otitis media associated with ANCA-associated vasculitis (OMAAV) [ 21, 22]. No significant associations were found between disease duration and changes in pure-tone thresholds or OAEs, suggesting that cochlear dysfunction may occur independently of disease duration in at least a subset of patients ( Table 5). Collectively, our findings indicate that hearing impairment in AAV is most consistent with immune-mediated cochlear microvascular dysfunction, characterized by preferential high-frequency involvement and limited but potentially reversible recovery following induction therapy. These observations support the incorporation of high-frequency audiometry into routine monitoring protocols and highlight the need for early detection strategies aimed at preserving cochlear function in this patient population. 5. Study Limitations This study has several limitations. First, the relatively small sample size reflects the rarity of ANCA-associated vasculitis and the prospective design, which may have limited the statistical power to detect significant associations between clinical and audiologic variables. Second, the heterogeneity of the study population, including differences in disease phenotype, treatment regimens, and disease duration, may have contributed to variability in hearing outcomes. Although all patients were evaluated during active disease and achieved remission, the timing and extent of cochlear recovery may differ between individuals and could not be fully captured within the study timeframe. Third, while a comprehensive audiologic test battery was applied, some measures—particularly otoacoustic emissions—may show limited sensitivity in systemic inflammatory conditions, potentially affecting the detection of subtle cochlear changes. 6. Conclusions Monitoring hearing function and treatment outcomes constitutes a fundamental component of audiologic care, particularly in systemic inflammatory diseases with potential cochlear involvement. The use of established classification systems facilitates standardized outcome assessment and improves comparability across studies. In this context, grading systems developed for idiopathic sudden sensorineural hearing loss (SSNHL) may provide a valuable framework for evaluating hearing impairment in systemic conditions characterized predominantly by cochlear sensorineural pathology. In the present study, we applied the Hearing Improvement Criteria for SSNHL defined by the Ministry of Health and Welfare of Japan to assess hearing severity and treatment-related changes in patients with ANCA-associated vasculitis (AAV). Despite the relatively small sample size and the limited number of statistically significant findings, our results suggest that this classification system may represent a practical and clinically meaningful tool for describing hearing abnormalities and monitoring therapeutic response in AAV. We additionally explored potential associations between hearing outcomes and systemic disease parameters, including BVAS score, hearing loss grade, pattern of improvement, ANCA subtype, disease duration, and treatment modality. Most of these analyses did not demonstrate statistically significant relationships. This may reflect limited statistical power due to the modest cohort size rather than a true absence of association. Overall, our findings support the incorporation of structured hearing outcome criteria and high-frequency audiometric assessment into the clinical monitoring of patients with AAV. Larger, prospective studies are warranted to validate these observations and to further elucidate the relationship between systemic disease activity and cochlear dysfunction. Author Contributions M.S.K., K.L., J.U., D.J. and S.N. designed the work; M.S.K., M.S., P.R., S.K. and E.G. acquired and analyzed data; M.S., K.L., J.U., M.J., D.J. and S.N. drafted, revised and approved the manuscript; K.L., D.J. and S.N. agree to be accountable for all aspects of the work. All authors have read and agreed to the published version of the manuscript. Funding This research received no external funding. Institutional Review Board Statement The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Ethics Committee of Military Institute of Medicine—National Research Institute (protocol code KB/4/23 and date of approval 20 December 2023). Informed Consent Statement Informed consent was obtained from all subjects involved in the study. Data Availability Statement The data that supports the findings of this study is available upon request from the corresponding authors. The data is not publicly available due to privacy or ethical restrictions. Acknowledgments We would like to express our sincere gratitude to Aleksandra Rymarz, the Deputy Head of Department Nephrology, Dialysis and Internal Diseases of Medical University of Warsaw (Warsaw, Mazovia, PL), for her valuable contribution and engagement during the preliminary phase of the project. Conflicts of Interest The authors declare no conflicts of interest. Abbreviations The following abbreviations are used in this manuscript (alphabetical order): AAV ANCA-associated vasculitis ABRs Auditory brainstem responses ANCAs Antineutrophil cytoplasmic antibodies BVAS/WG Birmingham Vasculitis Activity Score for Wegener’s Granulomatosis CF Cyclophosphamide CG Control group CT Computed tomography CHL Conductive hearing loss DpOAE Distortion product otoacoustic emissions EGPA Eosinophilic granulomatosis with polyangiitis ENT Ear, nose, throat FEIAs Fluorescent-enzyme immunoassays GPA Granulomatosis with polyangiitis HFA High-frequency pure-tone audiometry MHL Mixed hearing loss MPA Microscopic polyangiitis (MPO)-ANCA Myeloperoxidase ANCAs OMAAV Otitis media ANCA-associated vasculitis (PR3)-ANCA Proteinase 3 ANCAs PTA Pure-tone average RTX Rituximab SG Study group SNHL Sensorineural hearing loss SSNHL Sudden sensorineural hearing loss SNR Signal–noise ratio SOAE Spontaneous otoacoustic emissions SPL Sound pressure level TEOAE Transient-evoked otoacoustic emissions References Harabuchi, Y.; Kishibe, K.; Komabayashi, Y. Clinical manifestations of granulomatosis with polyangiitis (Wegener’s granulomatosis) in the upper respiratory tract seen by otolaryngologists in Japan. Clin. Exp. Nephrol. 2013, 17, 663–666. [ Google Scholar] [ CrossRef] Greco, A.; Marinelli, C.; Fusconi, M.; Macri, G.; Gallo, A.; De Virgilio, A.; Zambetti, G.; de Vincentiis, M. Clinic manifestations in granulomatosis with polyangiitis. Int. J. Immunopathol. Pharmacol. 2016, 29, 151–159. [ Google Scholar] [ CrossRef] Yoshida, N.; Iino, Y. Pathogenesis and diagnosis of otitis media with ANCA-associated vasculitis. Allergol. Int. 2014, 63, 523–532. [ Google Scholar] [ CrossRef] [ PubMed] Hellmich, B.; Sanchez-Alamo, B.; Schirmer, J.H.; Berti, A.; Blockmans, D.; Cid, M.C.; Holle, J.U.; Hollinger, N.; Karadag, O.; Kronbichler, A.; et al. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann. Rheum. Dis. 2023, 83, 30–47. [ Google Scholar] [ CrossRef] Kitoh, R.; Nishio, S.-Y.; Ogawa, K.; Kanzaki, S.; Hato, N.; Sone, M.; Fukuda, S.; Hara, A.; Ikezono, T.; Ishikawa, K.; et al. Nationwide epidemiological survey of idiopathic sudden sensorineural hearing loss in Japan. Acta Otolaryngol. 2017, 137, S8–S16. [ Google Scholar] [ CrossRef] Okada, M.; Hato, N.; Nishio, S.-Y.; Kitoh, R.; Ogawa, K.; Kanzaki, S.; Sone, M.; Fukuda, S.; Hara, A.; Ikezono, T.; et al. The effect of initial treatment on hearing prognosis in idiopathic sudden sensorineural hearing loss: A nationwide survey in Japan. Acta Otolaryngol. 2017, 137, S30–S33. [ Google Scholar] [ CrossRef] Robson, J.C.; Grayson, P.C.; Ponte, C.; Suppiah, R.; Craven, A.; Judge, A.; Khalid, S.; Hutchings, A.; Watts, R.A.; Merkel, P.A.; et al. 2022 American college of rheumatology/European alliance of associations for rheumatology classification criteria for granulomatosis with polyangiitis. Ann. Rheum. Dis. 2022, 81, 315–320. [ Google Scholar] [ CrossRef] [ PubMed] Suppiah, R.; Robson, J.C.; Grayson, P.C.; Ponte, C.; Craven, A.; Khalid, S.; Judge, A.; Hutchings, A.; A Merkel, P.; A Luqmani, R.; et al. 2022 American college of rheumatology/European alliance of associations for rheumatology classification criteria for microscopic polyangiitis. Ann. Rheum. Dis. 2022, 81, 321–326. [ Google Scholar] [ CrossRef] Stone, J.H.; Merkel, P.A.; Spiera, R.; Seo, P.; Langford, C.A.; Hoffman, G.S.; Kallenberg, C.G.; Clair, E.W.S.; Turkiewicz, A.; Tchao, N.K.; et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N. Engl. J. Med. 2010, 363, 168. [ Google Scholar] [ CrossRef] [ PubMed] Bénard, V.; Farhat, C.; Zarandi-Nowroozi, M.; Durand, M.; Charles, P.; Puéchal, X.; Guillevin, L.; Pagnoux, C.; Makhzoum, J. Comparison of Two Rituximab Induction Regimens for Antineutrophil Cytoplasm Antibody-Associated Vasculitis: Systematic Review and Meta-Analysis. ACR Open Rheumatol. 2021, 3, 484–494. [ Google Scholar] [ CrossRef] Floege, J.; Jayne, D.R.W.; Sanders, J.S.F.; Tesar, V.; Rovin, B.H. KDIGO 2024 Clinical Practice Guideline for the Management of Antineutrophil Cytoplasmic Antibody (ANCA)–Associated Vasculitis. Kidney Int. 2024, 105, S71–S116. [ Google Scholar] [ CrossRef] De Groot, K.; Harper, L.; Jayne, D.R.; Suarez, L.F.F.; Gregorini, G.; Gross, W.L.; Luqmani, R.; Pusey, C.D.; Rasmussen, N.; Sinico, R.A.; et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: A randomized trial. Ann. Intern. Med. 2009, 150, 670–680. [ Google Scholar] [ CrossRef] Stone, J.H.; Hoffman, G.S.; Merkel, P.A.; Min, Y.-I.; Uhlfelder, M.L.; Hellmann, D.B.; Specks, U.; Allen, N.B.; Davis, J.C.; Spiera, R.F.; et al. A disease-specific activity index for Wegener’s granulomatosis: Modification of the Birmingham Vasculitis Activity Score. Arthritis Rheum. 2001, 44, 912–920. [ Google Scholar] [ CrossRef] Humes, L.E. The World Health Organization’s hearing-impairment grading system: An evaluation for unaided communication in age-related hearing loss. Int. J. Audiol. 2019, 58, 12–20. [ Google Scholar] [ CrossRef] [ PubMed] ISO 7029:2017/Amd 1:2024; Acoustics—Statistical Distribution of Hearing Thresholds Related to Age and Gender—Amendment 1: Correction of Parameter Values for Estimating the Hearing Threshold Distribution. ISO: Geneva, Switzerland, 2024. Available online: https://www.iso.org/standard/86637.html (accessed on 1 March 2024). Tripathi, P.; Deshmukh, P. Sudden Sensorineural Hearing Loss: A Review. Cureus 2022, 14, e29458. [ Google Scholar] [ CrossRef] Cheng, Y.F.; Chu, Y.C.; Tu, T.Y.; Shiao, A.S.; Wu, S.L.; Liao, W.H. Modified Siegel’s criteria for sudden sensorineural hearing loss: Reporting recovery outcomes with matched pretreatment hearing grades. J. Chin. Med. Assoc. 2018, 81, 1008–1012. [ Google Scholar] [ CrossRef] Harabuchi, Y.; Kishibe, K.; Tateyama, K.; Morita, Y.; Yoshida, N.; Okada, M.; Kunimoto, Y.; Watanabe, T.; Inagaki, A.; Yoshida, T.; et al. Clinical characteristics, the diagnostic criteria and management recommendation of otitis media with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (OMAAV) proposed by Japan Otological Society. Auris Nasus Larynx 2021, 48, 2–14. [ Google Scholar] [ CrossRef] Kaczmarczyk, M.S.; Krzywdzińska, S.; Rozbicki, P.; Usowski, J.; Jadczak, M.; Jurkiewicz, D.; Sobol, M.; Niemczyk, S.; Głuch, E.; Leśniak, K. Hearing Involvement in Active ANCA-Associated Vasculitis: The Role of High-Frequency Audiometry in Early Detection. J. Clin. Med. 2026, 15, 2147. [ Google Scholar] [ CrossRef] Yoshida, N.; Hara, M.; Hasegawa, M.; Matsuzawa, S.; Shinnabe, A.; Kanazawa, H.; Iino, Y. Reversible cochlear function with ANCA-associated vasculitis initially diagnosed by otologic symptoms. Otol. Neurotol. 2014, 35, 114–120. [ Google Scholar] [ CrossRef] [ PubMed] Seccia, V.; Fortunato, S.; Cristofani-Mencacci, L.; Dallan, I.; Casani, A.P.; Latorre, M.; Paggiaro, P.; Bs, M.L.B.; Sellari-Franceschini, S.; Baldini, C. Focus on audiologic impairment in eosinophilic granulomatosis with polyangiitis. Laryngoscope 2016, 126, 2792–2797. [ Google Scholar] [ CrossRef] [ PubMed] Vainutienė, V.; Lesinskas, E.; Ivaškienė, T.; Mieliauskaitė, D.; Dadonienė, J.; Miltinienė, D.; Ivaška, J. Association Between Hearing Loss and Systemic Small-Vessel Vasculitis: Audiological Aspects Across Disease Types. Medicina 2025, 61, 1117. [ Google Scholar] [ CrossRef] Figure 1. Patient flow diagram. Figure 1. Patient flow diagram. Table 1. Organ involvement according to hearing loss. Table 1. Organ involvement according to hearing loss. Organ/System Involvement Hearing Status Normal Hearing ( n = 9) Hearing Loss ( n = 18) p eye Absent 8 (88.9%) 18 (100%) 0.333 Present 1 (11.1%) 0 (0%) CNS Absent 8 (88.9%) 15 (83.3%) 0.593 Present 1 (11.1%) 3 (16.7%) joints Absent 5 (55.6%) 10 (55.6%) 0.660 Present 4 (44.4%) 8 (44.4%) gastrointestinal tract Absent 9 (100%) 17 (94.4%) 0.667 Present 0 (0%) 1 (5.6%) heart Absent 9 (100%) 15 (83.3%) 0.279 Present 0 (0%) 3 (16.7%) peripheral nervous system Absent 8 (88.9%) 9 (50%) 0.057 Present 1 (11.1%) 9 (50%) kidneys Absent 2 (22.2%) 5 (27.8%) 0.571 Present 7 (77.8%) 13 (72.2%) skin Absent 6 (66.7%) 13 (72.2%) 0.774 Present 3 (33.3%) 5 (27.8%) paranasal sinuses Absent 5 (55.6%) 7 (38.9%) 0.340 Present 4 (44.4%) 11 (61.1%) lungs Absent 2 (22.2%) 4 (22.2%) 0.695 Present 7 (77.8%) 14 (77.8%) Table 2. Hearing loss improvement between first and second visit. Table 2. Hearing loss improvement between first and second visit. Hearing Loss Grade Visit G1 ( n = Ears) G2 ( n = Ears) G3 ( n = Ears) p First 39 (78%) 6 (12%) 5 (10%) 0.52 Second 43 (86%) 3 (6%) 4 (8%) Table 3. Hearing loss improvement according to hearing loss grade. Table 3. Hearing loss improvement according to hearing loss grade. Grade Improvement Ears PTA 500–4000 [ n = 50 Ears] Improvement Ears PTA 9000–12,500 [ n = 35 Ears] No Change Slight Improvement Marked Improvement Complete Recovery No Change Slight Improvement Marked Improvement Complete Recovery I 38 (97.4%) 1 (2.6%) 36 (92.3%) 3 (7.7%) II 3 (50%) 3 (50%) 3 (50%) 3 (50%) III 5 (100%) 0(0%) 5 (100%) 0(0%) IV Table 4. Otoacoustic emissions improvement between first and second visits. Table 4. Otoacoustic emissions improvement between first and second visits. Visit Overall TEOAE Response ( n = Ears) p Overall DPOAE Response ( n = Ears) p First 18 37.5% 0.555 23 50.0% 0.676 Second 20 43.5% 25 54.4% Table 5. Audiometric changes according to time to diagnosis of ANCA-associated vasculitis. Table 5. Audiometric changes according to time to diagnosis of ANCA-associated vasculitis. Audiometric Test Variable Time to Diagnosis Pre-Treatment p Group 1 (Disease Duration > 2 Months) ( n = Ears) Group 2 (Disease Duration < 2 Months) ( n = Ears) Tympanometry B 4 (16.7%) 2 (10.5%) 0.001 Tympanometry C 1 (4.2%) 4 (21.1%) Tympanometry A 17 (70.8%) 8 (42.1%) Tympanometry As 1 (4.2%) 3 (15.8%) Tympanometry Ad 1 (4.2%) 2 (10.5%) OVERALL DPOAE response 14 (58.3%) 9 (40.9%) 0.238 OVERALL TEOAE response 11 (42.3%) 7 (31.8%) 0.330 PTA normal hearing 11 (42.3%) 11 (45.8%) 0.762 PTA sensorineural hearing loss 8 (30.8%) 4 (16.7%) PTA conductive hearing loss 3 (11.5%) 6 (25%) PTA mixed hearing loss 4 (15.4%) 3 (12.5%) Post-treatment Tympanometry B 3 (12.5%) 3 (15%) 0.002 Tympanometry C 0 (0%) 0 (0%) Tympanometry A 18 (75%) 9 (45%) Tympanometry As 2 (8.3%) 2 (10%) Tympanometry Ad 1 (4.2%) 6 (30%) OVERALL DPOAE response ( n = ears) 14 (58.3%) 11 (50%) 0.571 OVERALL TEOAE response ( n = ears) 14 (58.3%) 6 (27.3%) 0.034 PTA normal hearing 13 (50%) 11 (45.8%) 0.792 PTA sensorineural hearing loss 5 (19.2%) 6 (25%) PTA conductive hearing loss 1 (11.5%) 5 (20.8%) PTA mixed hearing loss 5 (19.3%) 2 (8.3%) Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license. Share and Cite MDPI and ACS Style Kaczmarczyk, M.S.; Krzywdzińska, S.; Rozbicki, P.; Usowski, J.; Jadczak, M.; Jurkiewicz, D.; Sobol, M.; Niemczyk, S.; Głuch, E.; Leśniak, K. Hearing Outcomes During Induction Therapy in ANCA-Associated Vasculitis: Applicability of Sudden Sensorineural Hearing Loss Criteria. J. Clin. Med. 2026, 15, 4349. https://doi.org/10.3390/jcm15114349 AMA Style Kaczmarczyk MS, Krzywdzińska S, Rozbicki P, Usowski J, Jadczak M, Jurkiewicz D, Sobol M, Niemczyk S, Głuch E, Leśniak K. Hearing Outcomes During Induction Therapy in ANCA-Associated Vasculitis: Applicability of Sudden Sensorineural Hearing Loss Criteria. Journal of Clinical Medicine. 2026; 15(11):4349. https://doi.org/10.3390/jcm15114349 Chicago/Turabian Style Kaczmarczyk, Michał Stanisław, Sandra Krzywdzińska, Paweł Rozbicki, Jacek Usowski, Marcin Jadczak, Dariusz Jurkiewicz, Maria Sobol, Stanisław Niemczyk, Elżbieta Głuch, and Ksymena Leśniak. 2026. "Hearing Outcomes During Induction Therapy in ANCA-Associated Vasculitis: Applicability of Sudden Sensorineural Hearing Loss Criteria" Journal of Clinical Medicine 15, no. 11: 4349. https://doi.org/10.3390/jcm15114349 APA Style Kaczmarczyk, M. S., Krzywdzińska, S., Rozbicki, P., Usowski, J., Jadczak, M., Jurkiewicz, D., Sobol, M., Niemczyk, S., Głuch, E., & Leśniak, K. (2026). Hearing Outcomes During Induction Therapy in ANCA-Associated Vasculitis: Applicability of Sudden Sensorineural Hearing Loss Criteria. Journal of Clinical Medicine, 15(11), 4349. https://doi.org/10.3390/jcm15114349 Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here. Article Metrics Article metric data becomes available approximately 24 hours after publication online.
